We are a full-stack dementia care company. An estimated 7.4 million Americans age 65 and older are living with Alzheimer's dementia today, and that number could reach 13.8 million by 2060 absent a medical breakthrough. Health care, long-term care, and hospice payments for this population are projected at $409 billion in 2026 — with Medicare and Medicaid covering roughly $263 billion of it and families paying about $103 billion out of pocket. That figure doesn't count the ~13 million unpaid caregivers who provided more than 19 billion hours of care in 2025, work valued at over $446 billion.
Those numbers describe a system that doesn't exist. Dementia care in America is a patchwork of neurologists, primary care, social workers, home aides, adult day programs, benefits paperwork, and a spouse or adult child holding it all together with a spiral notebook. People are diagnosed an average of 3.5 years after symptoms first appear, and more than half of diagnoses in primary care come only after the disease has reached moderate or advanced stages — past the window where the newest disease-modifying therapies can help at all.
We're building the company that should exist instead: clinical care, care navigation, and software as one integrated stack. We work with patients and families across the country and are rapidly expanding our footprint with hospital systems and neurology clinics. We have an exclusive partnership with Johns Hopkins, and we're a Series A company backed by top-tier investors including Y Combinator.
Why this is the moment
Three things changed at once, and the infrastructure to take advantage of them hasn't been built yet:
- Payment finally exists. CMS launched the GUIDE Model (Guiding an Improved Dementia Experience) in July 2024 — a nationwide, eight-year model running through 2032 with roughly 390 participating organizations. It's one of the first CMMI models built around longitudinal, condition-specific care, and it pays per-member-per-month for exactly the things that were previously unbillable: comprehensive care plans, a dedicated care navigator, 24/7 access to the care team, and caregiver respite.
- Diagnosis is moving to the blood. The FDA cleared the first blood-based biomarker tests for Alzheimer's — Fujirebio's Lumipulse pTau217/β-amyloid ratio, followed in October 2025 by Roche's Elecsys pTau181 for use in primary care. Detection is moving out of academic memory centers and into everyday clinical settings, at enormous volume.
- There's something to do after the diagnosis. Lecanemab (2023) and donanemab (2024) both have full FDA approval, and as of May 2026 there were 158 additional Alzheimer's drugs in clinical trials, 73% of them aiming to slow progression. Meanwhile the specialist workforce — neurologists, geriatricians, geriatric psychiatrists — is nowhere near large enough to absorb the demand, and the shortfall varies enormously by geography.
Earlier detection plus real treatment options plus a payment model plus a specialist shortage equals a problem that has to be solved with software and a distributed care team. That's what we do.